Skip to main content
Top
Published in: BMC Gastroenterology 1/2023

Open Access 01-12-2023 | Proton Pump Inhibitors | Research article

Food elimination diet is a viable alternative therapy for eosinophilic esophagitis responsive to proton pump inhibitors

Authors: Twan Sia, Evan Cunningham, Megan Miller, Rebecca Nitschelm, Riki Tanaka, Taylor Epstein, Kendall Garrett, Amy Huang, Daniel Pak, Ally Scheve, John Leung

Published in: BMC Gastroenterology | Issue 1/2023

Login to get access

Abstract

Background

First-line treatment of eosinophilic esophagitis (EoE) includes monotherapy with proton-pump inhibitors (PPIs), food elimination diet (FED), or topical corticosteroids. Current guidelines suggest patients with EoE should continue any responsive first-line monotherapies. However, the efficacy of FED monotherapy in patients with EoE responsive to PPI monotherapy has not been well studied. Our study aimed to investigate how attempting FED monotherapy after experiencing remission of EoE after PPI monotherapy influenced long-term EoE management.

Methods

We retrospectively identified patients with EoE responsive to PPI monotherapy who trialed FED monotherapy. We then employed a mixed method approach to a prospective cohort. Selected patients were observed long term for quantitative outcomes, while qualitative results were obtained from patient surveys regarding their perspectives on the trial of FED monotherapy.

Results

We identified 22 patients who trialed FED monotherapy after experiencing remission of EoE following PPI monotherapy. Of these 22 patients, 13 had remission of EoE with FED monotherapy, while 9 had re-activation of EoE. Out of 22 patients, 15 were enrolled in a cohort for observation. No exacerbations of EoE occurred while on maintenance treatment. Most patients stated that they would recommend this process to others with EoE (93.33%) and that trial of FED monotherapy helped them identify a treatment plan that aligned with their lifestyle (80%).

Conclusion

Our work shows that FED monotherapy can be an effective alternative for patients with EoE responsive to PPI monotherapy that may improve patient quality of life, suggesting alternative treatment options should be considered for monotherapy-responsive EoE.
Appendix
Available only for authorised users
Literature
1.
go back to reference Biedermann L, Straumann A, Greuter T, Schreiner P. Eosinophilic esophagitis–established facts and new horizons. Semin Immunopathol. 2021;43:319–35.CrossRefPubMedPubMedCentral Biedermann L, Straumann A, Greuter T, Schreiner P. Eosinophilic esophagitis–established facts and new horizons. Semin Immunopathol. 2021;43:319–35.CrossRefPubMedPubMedCentral
3.
go back to reference Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–58.CrossRefPubMedPubMedCentral Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017;5(3):335–58.CrossRefPubMedPubMedCentral
4.
go back to reference Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterol. 2020;158:1776–86.CrossRef Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Gastroenterol. 2020;158:1776–86.CrossRef
5.
go back to reference Franciosi JP, Mougey EB, Dellon ES, et al. Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. J Asthma Allergy. 2022;15:281–302.CrossRefPubMedPubMedCentral Franciosi JP, Mougey EB, Dellon ES, et al. Proton pump inhibitor therapy for eosinophilic esophagitis: history, mechanisms, efficacy, and future directions. J Asthma Allergy. 2022;15:281–302.CrossRefPubMedPubMedCentral
6.
go back to reference Molina-Infante J, Arias A, Alcedo J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–72.CrossRefPubMed Molina-Infante J, Arias A, Alcedo J, et al. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2-4-6 study. J Allergy Clin Immunol. 2018;141(4):1365–72.CrossRefPubMed
7.
8.
go back to reference Philpott H, Dellon ES. The role of maintenance therapy in eosinophilic esophagitis: who, why, and how? J Gastroenterol. 2018;53:165–71.CrossRefPubMed Philpott H, Dellon ES. The role of maintenance therapy in eosinophilic esophagitis: who, why, and how? J Gastroenterol. 2018;53:165–71.CrossRefPubMed
9.
go back to reference Wang R, Hirano I, Doerfler B, Zalewski A, Gonsalves N, Taft T. Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis. Dig Dis Sci. 2018;63(7):1756–62.CrossRefPubMedPubMedCentral Wang R, Hirano I, Doerfler B, Zalewski A, Gonsalves N, Taft T. Assessing adherence and barriers to long-term elimination diet therapy in adults with eosinophilic esophagitis. Dig Dis Sci. 2018;63(7):1756–62.CrossRefPubMedPubMedCentral
10.
go back to reference Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110(5):626–32.CrossRefPubMed Jensen ET, Kappelman MD, Martin CF, Dellon ES. Health care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States. Am J Gastroenterol. 2015;110(5):626–32.CrossRefPubMed
11.
go back to reference Sodikoff J, Hirano I. Proton pump inhibitor–responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137(2):631–3.CrossRefPubMed Sodikoff J, Hirano I. Proton pump inhibitor–responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin Immunol. 2016;137(2):631–3.CrossRefPubMed
12.
go back to reference Iglesia EGA, Reed CC, Nicolai E, Dellon ES. Dietary elimination therapy is effective for a majority of proton pump inhibitor-responsive adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2020;18(7):1638-1640.e2.CrossRefPubMed Iglesia EGA, Reed CC, Nicolai E, Dellon ES. Dietary elimination therapy is effective for a majority of proton pump inhibitor-responsive adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2020;18(7):1638-1640.e2.CrossRefPubMed
13.
go back to reference Eke R, Li T, White A, Tariq T, Markowitz J, Lenov A. Systematic review of histological remission criteria in eosinophilic esophagitis. JGH Open. 2018;2(4):158–65.CrossRefPubMedPubMedCentral Eke R, Li T, White A, Tariq T, Markowitz J, Lenov A. Systematic review of histological remission criteria in eosinophilic esophagitis. JGH Open. 2018;2(4):158–65.CrossRefPubMedPubMedCentral
14.
go back to reference Ma C, Schoepfer AM, Dellon ES, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2022;149(2):659–70.CrossRefPubMed Ma C, Schoepfer AM, Dellon ES, et al. Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol. 2022;149(2):659–70.CrossRefPubMed
15.
go back to reference Reed CC, Wolf WA, Cotton CC, et al. Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study. Clin Gastroenterol Hepatol. 2018;16(2):226-233.e2.CrossRefPubMed Reed CC, Wolf WA, Cotton CC, et al. Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study. Clin Gastroenterol Hepatol. 2018;16(2):226-233.e2.CrossRefPubMed
Metadata
Title
Food elimination diet is a viable alternative therapy for eosinophilic esophagitis responsive to proton pump inhibitors
Authors
Twan Sia
Evan Cunningham
Megan Miller
Rebecca Nitschelm
Riki Tanaka
Taylor Epstein
Kendall Garrett
Amy Huang
Daniel Pak
Ally Scheve
John Leung
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2023
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-023-02703-9

Other articles of this Issue 1/2023

BMC Gastroenterology 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.